AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high) tumours due to their imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoniotti, Carlotta, Borelli, Beatrice, Rossini, Daniele, Pietrantonio, Filippo, Morano, Federica, Salvatore, Lisa, Lonardi, Sara, Marmorino, Federica, Tamberi, Stefano, Corallo, Salvatore, Tortora, Giampaolo, Bergamo, Francesca, Brunella, Di Stefano, Boccaccino, Alessandra, Grassi, Elisa, Racca, Patrizia, Tamburini, Emiliano, Aprile, Giuseppe, Moretto, Roberto, Boni, Luca, Falcone, Alfredo, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376656/
https://www.ncbi.nlm.nih.gov/pubmed/32698790
http://dx.doi.org/10.1186/s12885-020-07169-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376656/
https://www.ncbi.nlm.nih.gov/pubmed/32698790
http://dx.doi.org/10.1186/s12885-020-07169-6

Ejemplares similares